Neuralstem raises $5.135 million to help fund first human trial
Washington Business Journal - 12:16 PM EDT Tuesday, March 20, 2007by
Neil AdlerStaff Reporter
Print this Article Email this Article Reprints RSS Feeds Most Viewed Most Emailed
Neuralstem hopes to begin its first human clinical trial on a stem cell product sometime this year and has raised more than $5 million to help fund the trial.

The Rockville-based biotechnology company, whose focus is treatments
based on the transplantation of human neural stem cells, raised about $5.14 million in a private placement of more than 2 million units at $2.50 per unit to a group of institutional investors.

Each unit consists of one share of common stock and one half-warrant
exercisable at $3 per share. Bedminster, N.J.-based T.R. Winston and Co. acted as the placement agent for the offering. .............

Link : http://washington.bizjournals.com/wa...8&surround=etf